XIENCE V vs TAXUS: Game Over! The Studies are Definitive Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular Santa Clara, CA CRT 2010

Charles A. Simonton, MD DISCLOSURES Chief Medical Officer Abbott Vascular Santa Clara, CA

It’s All About Level of Evidence = A The data now available for the direct comparison of clinical outcomes comparing Xience V and Taxus is the best we’ve ever had in head-to-head DES clinical trials WHY? Prospective, randomized, multicenter trials Adequately powered for both angiographic and clinical endpoints (SPIRIT II, III, IV and COMPARE) SPIRIT IV is the largest prospective, randomized, multicenter head-to-head DES trial ever completed that is fully powered for a primary clinical endpoint

XIENCE: Best-in-Class Components

XIENCE V: Thinnest Struts of Any DES1 CYPHER TAXUS Liberté ENDEAVOR XIENCE V Strut Thickness: 140 mm Coating Thickness: 12.6 mm Strut Thickness: 97 mm Coating Thickness: 17.8 mm Strut Thickness: 91 mm Coating Thickness: 4.8 mm Strut Thickness: 81 mm Coating Thickness: 7.8 mm NEED LIBERTE picture. Total = 152.6 um 114.8 um 95.8 um 88.8 um 3.0 mm diameter stents, 500x magnification 1Manufacturer-reported strut thickness. Data on file at Abbott Vascular.

XIENCE V: 14-Day Rabbit Iliac Re-endothelialization Study CYPHER TAXUS ENDEAVOR XIENCE V Joner et al, JACC 2008 Photos taken by and on file at Abbott Vascular

Investment in Clinical Programs: Worldwide DES Clinical Trials NOTE: For trials that have completed enrollment, numbers are final enrollment. For trials that are planned or still enrolling, numbers are per protocol XIENCE to be studied in ~29,000 patients Pre-Approval Post-Market Trial Name # of Enrolling Sites # of Patients Time Patients Followed Trial Name # of Enrolling Sites # of Patients Time Patients Followed SPIRIT V SPIRIT Women XIENCE V USA 2 XIENCE V India XIENCE V China XIENCE V Japan XIENCE V EXCEED FAR XIENCE V 1 XERES 1 EXECUTIVE 1 102 100 250 19 TBD 110 58 24 30 3,025 2,000 ~8,000 1,000 ~2,450 ~1,900 2,500 1,200 100 600 5 yrs 3 yrs Acute 2 yrs SPIRIT FIRST 1 SPIRIT II SPIRIT III SPIRIT III Japan SPIRIT IV SPIRIT Small Vessel SPIRIT PRIME 9 28 65 12 58 50 75 60 300 1,002 88 3,690 250 500 5 yrs 1 European Study 2 XIENCE V USA will include a DAPT subset; 5-year patient follow-up on a subset; additional subsets have 33-month or 12-month follow-up Note: This product is currently CE marked. Where CE marking is not the registration in force, this product may be in Abbott Vascular’s pipeline. For trials that have completed enrollment, numbers are final enrollment. For trials that are planned or still enrolling, numbers are per protocol 7

SPIRIT III Trial Design & Demographics 2 : 1 XIENCE V (N = 669) TAXUS (Control = 333) Up to two de novo lesions, maximum of one lesion per epicardial vessel RVD: 2.5 – 3.75 mm LL: 28 mm N = 1,002 65 US sites PI: Gregg Stone, MD RCT: Prospective, single blind Primary end point: In-segment Late Loss at 8M Stent Size: 2.5 – 3.5 mm; Stent lengths: 8, 18, 28 mm Angiographic and IVUS Follow-Up on 564 and 240 pts, respectively Clinical follow-up at 30, 180, 270d and 1, 2, 3, 4 and 5 years 6 Months clopidogrel for all arms SPIRIT III Trial Objective To determine the safety and efficacy of the ML XIENCE V™ EECS System in patients with de novo native coronary artery lesions. SPIRIT III was the pivotal trial in the US for FDA approval. XIENCE V TAXUS P-Value Patients 669 332 NA RVD (mm)* 2.77 ±0.5 2.76 ±0.5 Lesion Length (mm)* 14.7 ±5.6 14.7 ±5.7 Diabetics 29.6% 27.9% 0.60% 8 Taxus Express2 was used as the control in SPIRIT III. *SOURCE: Stone, Gregg, JAMA. Vol 299, No. 16 8

SPIRIT III 3-Year Major Adverse Cardiac Events XIENCE V® TAXUS® 3-year HR 2-year HR 0.57 [0.39, 0.83] 0.55 [0.37, 0.82] p=0.003 1-year HR p=0.003 0.56 [0.35, 0.90] 15.7% 13.1% p=0.01 MACE (%) ∆6.6% 9.9% ∆5.6% ∆4.2% 9.1% 7.5% XIENCE V: Delivers long term safety The difference in MACE between XIENCE V and TAXUS continues to widen between 1, 2 and 3 years with a 43% reduction in MACE at 3 years 5.7% Number at risk XIENCE V® 669 652 643 628 612 598 597 591 581 576 574 572 569 TAXUS® 332 312 308 291 286 275 272 269 266 264 260 258 255 Months 9 Taxus Express2 was used as the control in SPIRIT III. SOURCE: Gregg Stone SPIRIT III 3 Year Results TCT 2009 9

Taxus Express2 was used as the control in SPIRIT III. SPIRIT III 3-Year Landmark Analysis Stent Thrombosis (ARC) 0.3% VLST (ARC Definite + Probable) 0% S.T. between years 2 & 3 in 669 pts TAXUS XIENCE V 1-year HR 1.48 [0.30, 7.31] p=0.63 2-year HR 0.32 [0.05, 1.93] p=0.19 3-year HR 0.32 [0.05, 1.93] p=0.19 Stent Thrombosis (%) 0.15% per year = BMS-like 1.0% 1.0% Low 0.3% very late stent thrombosis rates (ARC Def/Prob) between 1 and 3 years; 0% stent thrombosis rate from 2 to 3 years in 669 patients XIENCE V had a low 0.3% rate of stent thrombosis between 1 and 3 years, no new ST from years 2 to 3. 0.9% ∆0.7% ∆0.7% ∆-0.6% 0.3% 0.3% 0.3% Months Taxus Express2 was used as the control in SPIRIT III. SOURCE: David Cox SPIRIT III 3 Year Results TCT 2009

SPIRIT IV XIENCE V TAXUS Randomized 2:1 XIENCE V:TAXUS Express2 ***Clinical f/u only: 1, 6, 9 months and yearly for 1-5 years ***Pt. driven events not impacted by angiographic F/U ***Largest RCT to comparing two DES (↑ diabetic pop.) 100% monitoring: reflects high quality data arising from this trial RVD ≥2.5 mm - ≤3.75 mm; Lesion length ≤28 mm Max. 3 lesions with a maximum of 2 per epicardial vessel Pre-rand: ASA ≥300 mg, clopidogrel ≥300 mg load unless on chronic Rx 3690 pts enrolled at 66 U.S. sites Randomized 2:1 XIENCE V:TAXUS Express2 Stratified by diabetes and presence of complex lesions Pre-dilatation mandatory Everolimus-eluting XIENCE V Paclitaxel-eluting TAXUS SPIRIT IV Trial Design Key Messages Largest RCT between two DES to have presented primary endpoint data One of the largest subsets of patients with diabetes (n=1185 enrolled) Clinically-driven primary and secondary endpoints – Patient driven events not impacted by angiographic follow-up 100% monitoring – Reflective of the quality of data arising from the trial Aspirin ≥80 mg QD for 5 years; clopidogrel 75mg QD for at least 12 mos (if not at high risk for bleeding) 11 SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 11 11

Target lesion failure (%) SPIRIT IV: Primary Endpoint (TLF) Early & Continuously Divergent Differences HR [95%CI] = 0.61 [0.46, 0.82] XIENCE V TAXUS p=0.0008 TLF = cardiac death, target vessel MI, and ischemia-driven TLR 6.6% Number Needed to Treat (NNT) to prevent one TLF Event = 37 Target lesion failure (%) Δ 2.7% TAXUS 3.9% XIENCE V XIENCE V delivers clinical superiority in the largest RCT between two DES to have presented primary endpoint data. XIENCE V proved superior to TAXUS in the clinically-driven primary endpoint of target lesion failure (TLF) (3.9% vs. 6.6%, p=0.0008) Months XIENCE V 2458 2390 2362 2323 2298 TAXUS 1229 1165 1137 1119 1104 SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009

SPIRIT IV TLF Components 39% ↓ in TLF driven by a 38% ↓ in TV-MI and a 46% ↓ in ID-TLR XIENCE V TAXUS RR [95%CI] = 0.55 [0.38, 0.78] p=0.001 RR [95%CI] = 0.62 [0.40, 0.96] p=0.04 46% Reduction TLF = cardiac death, target vessel MI, and ischemia-driven TLR 1 Year = 365 ± 28 days 38% Reduction % RR [95%CI] = 0.99 [0.34, 2.89] p=1.00 39% reduction in the risk of TLF driven by reductions in ID-TLR (2.5% vs. 4.6%, p=0.001) and Target Vessel MI (1.8% vs. 2.9%, p=0.04) 10/2416 5/1195 44/2416 35/1195 61/2416 55/1195 Cardiac Death Target Vessel MI ID-TLR 13 SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 13 13

NNT (number needed to treat) to avoid 1 ST is only 125 Patients SPIRIT IV Stent Thrombosis: ARC Definite or Probable XIENCE V TAXUS HR [95%CI] = 0.27 [0.11, 0.67] p=0.003 NNT (number needed to treat) to avoid 1 ST is only 125 Patients TAXUS 1.06% Stent thrombosis (%) ≈73% ↓ in S.T. at 1 year Δ 0.77% XIENCE V XIENCE V delivers long-term safety. 74% reduction in the risk of stent thrombosis (ARC def or prob) at 1 year SPIRIT IV (p=.004). 0.29% Months XIENCE V 2458 2426 2412 2388 2376 TAXUS 1229 1195 1184 1174 1166 SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009

SPIRIT IV 1-Year Impact of Diabetes on TLF XIENCE V TAXUS RR [95%CI] = 0.47 [0.32, 0.68] p<0.0001 RR [95%CI] = 0.94 [0.59, 1.49] p=0.80 TLF (%) 1,140 patients: 6.4% vs. 6.9% In 1,140 patients with diabetes at 1 year, XIENCE V demonstrated a low 6.4% rate of TLF (vs. 6.9% for TAXUS; p=0.80) 52/1652 55/815 49/761 26/379 Pinteraction = 0.02 TLF = cardiac death, target vessel MI, or ischemia-driven TLR 15 SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 15

COMPARE Trial XIENCE V vs. TAXUS Liberté AMI 25 % Calcification 34 % Multistenting 62 % Ostial 19 % Thrombus 24 % CTO 4 % NSTEMI 23 % Multivessel 27 % Saphenous graft 2 % Bifurcation 10 % Diabetes 18 % Chronic renal failure 3 % Left main 2 % Direct stenting 34 % “REAL WORLD” Therefore, we can say that the COMPARE trial truly reflects a real world situation with:……… 16 Smits P, Lancet 2010 SOURCE: Smits COMPARE Trial, TCT 2009 16

MACE (All death, non-fatal MI, and TVR) COMPARE: XIENCE V vs. TAXUS Liberté Primary Endpoint (MACE = Death, MI and TVR) Taxus XIENCE 31% ↓ in MACE, p= 0.023 P = 0.023 (log-rank test) RR = 0.69 (0.50-0.95) 9.1 % Δ 2.9 % Δ 1.1% 6.2 % XIENCE V is superior to TAXUS Liberté in 1,800 real-world, all comer patients 31% reduction in the primary endpoint of MACE (p=.023) 74% reduction in the secondary endpoint of stent thrombosis (p=0.002) Benefits of XIENCE V over TAXUS translated across platforms with compelling data in SPIRIT IV and COMPARE (TAXUS is TAXUS!) This is the result of the primary end-point: the combination of all death, non fatal MI and TVR. At 12 months follow up, a significant higher incidence of MACE occurred in the Taxus stent group compared to the Xience stent group. The MACE rate is 9.1% in Taxus versus 6.2% in Xience, which is significant different according the log rank test, with a rate ratio of 0.69 and 95% Confidence Interval of 0.50-0.95. Of interest is the early difference in events between both groups of 1.1% at 30 days, which gradually increased over time to 2.9% at 12 months follow-up . # Patients at Risk MACE (All death, non-fatal MI, and TVR) Taxus 903 868 865 860 853 849 842 838 833 825 823 822 819 Xience 897 872 870 867 865 864 858 854 851 849 844 842 840 17 SOURCE: Smits COMPARE Trial, TCT 2009 17

COMPARE: XIENCE V vs. TAXUS Liberté Secondary Endpoint (Stent Thrombosis) P = 0.002 (log-rank test) RR = 0.26 (0.11-0.64) 2.6 % NNT (number needed to treat) to prevent 1 ST Event is only 53 Patients 74% ↓ in risk of stent thrombosis at 1 year Definite & probable stent thrombosis rate according to the ARC definitions was also highly significant different between both groups, with a 2.6% in the Taxus group versus 0.7% in the Xience group. This is mainly due to a difference in early stent thrombosis, as shown ……(next dia) 0.7 % A.R.C. Definite & probable stent thrombosis SOURCE: Smits COMPARE Trial, TCT 2009 18

Xience V versus Taxus Clinical Data: Level of Evidence = A SPIRIT III – Angiographic superiority over Taxus with efficacy and safety proven long term (3-yrs) SPIRIT IV – Statistically-significant reduction in TLF and TLR as well as stent thrombosis compared to Taxus, thus showing both improved efficacy and safety, in the largest prospective RCT of DES to date COMPARE – Outstanding one year safety and efficacy data, again statistically-significant vs. TAXUS Liberte in a real world population 19

Xience V versus Taxus So, Keith, it’s time to put ‘ole Taxus’ out to pasture, as it just can’t keep up with the competition . . . Taxus

And, move on to an exciting new generation of technology! Xience V versus Taxus And, move on to an exciting new generation of technology! Xience V